gestational trophoblastic tumors

Avelumab Plus Methotrexate in Low-Risk Gestational Trophoblastic Tumors: A Promising First-Line Signal From TROPHAMET

TROPHAMET found that first-line avelumab plus methotrexate achieved 96.2% hCG normalization in low-risk gestational trophoblastic tumors with manageable toxicity, no relapses at 41 months, and preserved fertility.